Daxor (DXR) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 1.99K
• Price to Earnings (P/E): 30.9
• Beta (1Y): 0.60
• Revenue Growth: -97.00%
• EPS Growth: 3.43%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 5,827,225
• 10 Day Avg. Volume: 865
• 30 Day Avg. Volume: 1,994
• PEG Ratio: 0.85
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 17.48
• P/FCF Ratio: 1.45K
• Enterprise Value/Market Cap: 10.00T>
• Enterprise Value/Revenue: 81.21
• Enterprise Value/Gross Profit: 90.70
• Enterprise Value/Ebitda: 17.35
• 1Y Price Target: $23.00
• Price Target Upside: 73.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $12.50 ▼(-5.87% Downside)
• Action: Downgraded Date: 01/27/26
• Date: Action: Downgraded 01/27/26

Overall score is held back mainly by inconsistent cash generation and highly volatile operating results, partially offset by a strong, low-leverage balance sheet. Technicals remain weak with the stock below key moving averages, and valuation is not especially supportive at a higher P/E without a dividend. A recent compliance-related filing is a small positive but not a core driver.

Positive Factors

Balance Sheet Strength

Very low leverage and a sizable equity base provide a material solvency buffer and financial optionality. This reduces refinancing and bankruptcy risk during revenue troughs, enabling the company to fund operations, maintenance, or selective investment without immediate external capital in the next 2–6 months.

Niche Medical Specialty

A concentrated product focus on blood volume measurement and clinical decision support targets complex, recurring clinical needs. Specialized devices plus disposables and service revenue create higher switching costs and recurring demand from hospitals, supporting durable installed‑base cash flows and clinical adoption over time.

Return to Profitability

Achieving positive net income and a healthy reported margin in 2024 demonstrates the business can operate profitably at current scale. Sustained profitability would indicate operating leverage and improve internal funding ability, reducing reliance on external capital if revenue stabilizes over subsequent quarters.

Negative Factors

Weak Cash Conversion

Operating cash flow was barely positive in 2024 and far below reported earnings, with a very low OCF-to-net-income ratio and prior multi‑year negative cash flow. Poor cash conversion constrains reinvestment, increases financing reliance, and weakens the firm’s ability to withstand revenue volatility over months.

Revenue and Earnings Volatility

Historical swings in revenue and operating results reduce predictability of future cash flows and make capacity planning and commercial investments risky. Such volatility complicates long‑term contract wins, reimbursement negotiations, and strategic partnerships, impeding steady market expansion over the medium term.

Small Scale and Low Liquidity

Very small organizational scale and limited trading liquidity constrain commercial reach, R&D resources, and the pace of hospital penetration. Limited scale increases execution risk, slows durable market share gains, and can raise the effective cost of capital or delay needed investments over a multi‑month horizon.

Daxor Business Overview & Revenue Model

Company Description

Daxor Corporation (DXR) is a medical instrumentation and biotechnology company that specializes in blood volume analysis technology. The company focuses on advancing healthcare by providing innovative diagnostic tools and services that enhance the understanding and treatment of various medical conditions. Daxor's flagship product, the BVA-100, is an FDA-cleared diagnostic device that measures human blood volume, aiding in the precise assessment of fluid management in patients.

How the Company Makes Money

Daxor Corporation generates revenue primarily through the sale and leasing of its proprietary blood volume analysis systems, such as the BVA-100. Additionally, the company earns income by providing related services, including testing and analysis of blood samples. This includes contracts with hospitals, clinics, and medical research institutions that utilize their technology for improved clinical decision-making. Daxor may also benefit from partnerships or collaborations with healthcare providers and research organizations that contribute to its growth and market reach. Factors such as regulatory approvals, technological advancements, and the increasing demand for precision in medical diagnostics play a significant role in its revenue generation.

Daxor Financial Statement Overview

Summary

Balance sheet strength (very low leverage, sizable equity base) supports solvency, but operating results are difficult to underwrite due to extreme revenue/profit volatility and weak, inconsistent cash conversion (recent operating/free cash flow often negative and 2024 OCF far below net income).

Income Statement

Profitability improved in 2024 with positive net income (~$0.54M) and a healthy net margin (~25%), and 2023 also stayed profitable. However, results are highly volatile: revenue swung sharply (2024 revenue fell dramatically versus 2023 despite an extreme growth-rate print off a small base), and earlier years show negative/erratic revenue with large profits/losses, making the earnings trajectory hard to underwrite with confidence.

Balance Sheet

The balance sheet is a clear strength: leverage is low (debt-to-equity ~2% in 2024) with a large equity base (~$35.8M) relative to debt (~$0.73M). Return on equity is modest in 2024 (~1.5%) versus stronger levels in 2021–2022, but overall solvency risk appears limited given the light debt load.

Cash Flow

Cash generation is inconsistent and often weak: operating cash flow was slightly positive in 2024 (~$0.03M) but far below net income (operating cash flow to net income ~0.23x), and 2021–2023 showed sizable negative operating/free cash flow. While 2019 generated strong positive cash flow, the recent pattern suggests earnings quality and cash conversion remain key risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	713.65K	2.13M	34.59M	-353.36K	-2.62M	-2.81M
Gross Profit	639.01K	2.13M	34.41M	-1.44M	-3.62M	-3.49M
EBITDA	3.34M	2.06M	329.74K	6.11M	4.75M	-1.72M
Net Income	1.80M	536.33K	280.64K	5.18M	4.75M	-1.71M
Balance Sheet
Total Assets	35.90M	36.63M	34.87M	30.26M	24.98M	16.55M
Cash, Cash Equivalents and Short-Term Investments	0.00	0.00	0.00	0.00	710.70K	617.80K
Total Debt	262.93K	729.97K	755.66K	1.23M	3.02M	170.69K
Total Liabilities	272.43K	840.30K	858.76K	1.29M	3.83M	877.69K
Stockholders Equity	35.63M	35.79M	34.01M	28.97M	21.15M	15.68M
Cash Flow
Free Cash Flow	-35.01K	25.69K	-3.66M	-769.30K	-2.76M	-2.45M
Operating Cash Flow	-35.01K	25.69K	-3.66M	-769.30K	-2.76M	-2.45M
Investing Cash Flow	2.20M	1.94M	2.75M	2.69M	74.76K	367.93K
Financing Cash Flow	-1.39M	-25.69K	3.66M	58.60K	2.85M	3.07M

Daxor Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXR, the sentiment is Negative. The current price of 13.28 is above the 20-day moving average (MA) of 12.23, above the 50-day MA of 13.00, and above the 200-day MA of 11.54, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 34.83 is Neutral, neither overbought nor oversold. The STOCH value of 9.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DXR.

Daxor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	68 Neutral	$4.45B	35.21	8.67%	―	11.49%	-2.89%
PDEX	66 Neutral	$152.32M	13.96	30.92%	―	23.65%	120.84%
DXR	52 Neutral	―	30.93	5.26%	―	-97.00%	3.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLSS	42 Neutral	$22.13M	-3.40	-136.47%	―	0.59%	-39.76%
FEMY	41 Neutral	$31.50M	-0.73	-376.23%	―	63.53%	12.49%

Daxor Corporate Events

Daxor Files Legal Opinion Affirming Validity of Stock

Daxor filed a legal opinion from Foley & Lardner LLP regarding the legality of its common stock, indicating that the company has obtained formal legal validation for the issuance or status of its shares. This filing helps reinforce regulatory compliance and may provide additional assurance to investors and other stakeholders about the legitimacy of Daxor’s common stock offering or existing equity structure.

The most recent analyst rating on (DXR) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Daxor stock, see the DXR Stock Forecast page.

Daxor Releases Updated Investor Presentation to Public Markets

Daxor Corporation disclosed that it has made its current investor presentation publicly available, without providing additional operational, financial, or strategic details in the accompanying text. The release signals an effort to update and engage investors, but the lack of substantive content in the filing means the implications for the company’s operations, industry positioning, or stakeholders cannot be determined from this document alone.

The most recent analyst rating on (DXR) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Daxor stock, see the DXR Stock Forecast page.